NEW YORK (GenomeWeb News) – The prenatal genetic testing company Cellscape said that Ted Snelgrove has become its new CEO, effective last week.

Snelgrove previously was VP of sales and marketing for Genomic Health, where he led the commercial development and launch of the Oncotype Dx test. He most recently was chief commercial officer for Crescendo Bioscience, and he has worked in business development, marketing, and product management at Amgen, ALZA, Immunex, and Eli Lilly.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.